American Century Investments ® VP Value Fund
Class I: AVPIX Class II: AVPVX	Class III: AVPTX

	Before you invest, you may want to review the fund’s prospectus, which contains more information about the fund and its risks. You can find the fund’s prospectus and other information about the fund online at the web addresses listed below. You can also get this information at no cost by calling or sending an email request. The fund’s prospectus and other information are also available from insurance companies through which shares of the fund may be purchased or sold.
	Retail Investors americancentury.com/funds/vp_fund_reports.jsp 1-800-378-9878 or 816-531-5575 prospectus@americancentury.com	Financial Professionals americancentury.com/ipro/funds/fund_reports_vp.jsp 1-800-345-6488 advisor_prospectus@americancentury.com
	This summary prospectus incorporates by reference the fund’s prospectus and statement of additional information (SAI), each dated May 1, 2013 (as supplemented at the time you receive this summary prospectus), as well as the Report of Independent Registered Public Accounting Firm and the financial statements included in the fund’s annual report to shareholders, dated December 31, 2012. The fund's SAI and annual report may be obtained, free of charge, in the same manner as the prospectus.

 The fund seeks long-term capital growth. Income is a secondary objective.

 The following table describes the fees and expenses you may pay if you buy and hold shares of the fund. The table does not include the fees and expenses associated with your variable annuity or variable life insurance contract. Had they been included, fees and expenses presented below would have been higher.

Shareholder Fees (fees paid directly from your investment)
	Class I	Class II	Class III
Redemption/Exchange Fee (as a percentage of amount redeemed/exchanged for shares held less than 60 days)	None	None	1.00%

Annual Fund Operating Expenses (expenses that you pay each year as a percentage of the value of your investment)
	Class I	Class II	Class III
Management Fee	0.97%	0.87%	0.97%
Distribution and Service (12b-1) Fees	None	0.25%	None
Other Expenses	0.01%	0.01%	0.01%
Total Annual Fund Operating Expenses	0.98%	1.13%	0.98%

 The example below is intended to help you compare the costs of investing in the fund with the costs of investing in other mutual funds. The example does not include fees and expenses associated with your variable annuity or variable life insurance contract. Had they been included, fees and expenses would have been higher. The example assumes that you invest $10,000 in the fund for the time periods indicated and then redeem all of your shares at the end of those periods, that you earn a 5% return each year, and that the fund’s operating expenses remain the same. Although your actual costs may be higher or lower, based on these assumptions your costs would be:

	1 year	3 years	5 years	10 years
Class I	$100	$313	$542	$1,201
Class II	$115	$360	$623	$1,374
Class III	$100	$313	$542	$1,201

 The fund pays transaction costs, such as commissions, when it buys and sells securities (or “turns over” its portfolio). A higher portfolio turnover rate may indicate higher transaction costs. These costs, which are not reflected in annual fund operating expenses or in the example, affect the fund’s performance. During the most recent fiscal year, the fund’s portfolio turnover rate was 47% of the average value of its portfolio.

In selecting stocks for the fund, the portfolio managers look for companies of all sizes whose stock price may not reflect the company’s value. The managers attempt to purchase the stocks of these undervalued companies and hold each stock until the price has increased to, or is higher than, a level the managers believe more accurately reflects the fair value of the company.

The portfolio managers may sell stocks from the fund’s portfolio if they believe a stock no longer meets their valuation criteria, a stock’s risk parameters outweigh its return opportunity, more attractive alternatives are identified or specific events alter a stock’s prospects.

•	Multi-Cap Investing – The fund is a multi-capitalization fund that invests in companies of all sizes. The small and medium-sized companies in which the fund invests may be more volatile and subject to greater risk than larger companies.
•	Style Risk – If the market does not consider the individual stocks purchased by the fund to be undervalued, the value of the fund’s shares may decline, even if stock prices generally are rising.
•	Foreign Securities – The fund may invest in foreign securities, which can be riskier than investing in U.S. securities.
•	Market Risk – The value of the fund’s shares will go up and down based on the performance of the companies whose securities it owns and other factors generally affecting the securities market.
•	Price Volatility – The value of the fund’s shares may fluctuate significantly in the short term.
•	Principal Loss – At any given time your shares may be worth less than the price you paid for them. In other words, it is possible to lose money by investing in the fund.

An investment in the fund is not a bank deposit, and it is not insured or guaranteed by the Federal Deposit Insurance Corporation (FDIC) or any other government agency.

The following bar chart and table provide some indication of the risks of investing in the fund. The bar chart shows changes in the fund’s performance from year to year for Class I shares. The table shows how the fund’s average annual returns for the periods shown compared with those of a broad measure of market performance. Fees associated with your variable annuity or variable life insurance contract are not reflected in the chart or table below. Had they been included, returns presented below would have been lower. The fund’s past performance is not necessarily an indication of how the fund will perform in the future.

Calendar Year Total Returns

Highest Performance Quarter (2Q 2003): 15.96% Lowest Performance Quarter (4Q 2008): -17.02%

Average Annual Total Returns
For the calendar year ended December 31, 2012	1 year	5 years	10 years
Class I	14.58%	2.87%	7.22%
Class II	14.58%	2.74%	7.06%
Class III	14.58%	2.87%	7.22%
Russell 3000 ® Value Index    (reflects no deduction for fees, expenses or taxes)	17.55%	0.83%	7.54%
S&P 500 ® Index    (reflects no deduction for fees, expenses or taxes)	16.00%	1.66%	7.10%

 Portfolio Management

 Investment Advisor

 American Century Investment Management, Inc.

Phillip N. Davidson , CFA, Chief Investment Officer-Value Equity, Senior Vice President and Senior Portfolio Manager, has been a member of the team that manages the fund since 1996.

Michael Liss , CFA, CPA, Vice President and Senior Portfolio Manager, has been a member of the team that manages the fund since 1998.

Kevin Toney , CFA, Vice President and Senior Portfolio Manager, has been a member of the team that manages the fund since 2003.

Chad Baumler, CFA, Portfolio Manager, has been a member of the team that manages the fund since 2007.

The fund only offers shares through insurance company separate accounts. For instructions on how to purchase and redeem shares through your separate account, read the prospectus provided by your insurance company. Orders for fund shares will be priced at the net asset value next determined after the order is received in the form required by the agreement between the fund, its investment advisor and/or its distributor and the insurance company from which you have purchased your separate account. There are no sales commissions or redemption charges except for Class III shares, which may be subject to a redemption fee. However, certain sales or deferred sales charges and other charges may apply to the variable annuity or life insurance contracts. Those charges are disclosed in the separate account prospectus.

Consult the prospectus of your insurance company separate account for a discussion of the tax status of your variable contract.

Payments to Broker-Dealers and Other Financial Intermediaries

The fund is offered as an underlying investment option for variable annuity or life insurance contracts. The fund and its related companies pay the sponsoring insurance company and its related companies for distribution and other services. These payments may influence the insurance company to include the fund over another investment as an option in its products. Ask your salesperson or visit your insurance company’s website for more information."

This sort of prospectus goes to show just how much work this company is putting into ensuring that investors are highly informed about their financial standing. With the sort of information that SPOM is putting forward for the public eye, Penny Stock Dream is very excited to have been able to have shed the light on this special penny stock, so early on. The other news item released by this company on the 11th, about revenue generation can be seen below:

NEW YORK, April 11, 2013 /PRNewswire/ --

SPO Medical Inc. (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, announced today financial results for the year ended December 31, 2012. During this period the Company completed development of its new wellness product and commenced sales activities.

Total revenue for 2012 was $316,000 compared to$20,000 for the same period in 2011. The increase in revenue was the result of the Company's strategy to enter the non-medical consumer wellness market through its partnership with HoMedics LLC. In addition, the Company has a backlog of firm orders of approximately $500,000 for planned shipments through 2013. The Company anticipates this backlog to increase during fiscal year 2013 as sales continue to grow in the United States and in international markets. This is primarily attributed to the expanded distribution of its private-labeled pulse oximeter known as the HoMedics Deluxe Pulse Oximeter for non-medical consumer wellness markets.

Further details as to SPO's financial information and results of operations for the fiscal year ended December 31, 2012 are in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 11, 2013.

Michael Braunold, Chief Executive Officer of SPO commented: "We are very pleased with our fiscal results for 2012 and backlog position which show a strategic turnaround for the Company - this was achieved in a relatively short period of time after our decision to distribute under the HoMedics private-label which gave us immediate access to mass-market retailers worldwide. We have also made our first shipment to the international market outside of the United States and we see further upside during 2013, by leveraging on our joint-success to date."

During 2013, SPO anticipates expanding other product opportunities currently under development and specifically its fitness watch - a new consumer wellness time-piece designed to measure overall daily activity level, especially useful for overweight and obese adults and children. This new and innovative product, already demonstrated to several retail category buyers, will include unique innovative features as well as being a fashionable time-piece to continuously measure the number of daily activities and calories burned against a recommended goal.

Braunold continued: "We see substantial opportunities to expand in the drugstore channel and beyond as we grow our product portfolio during 2013, particularly as our partner HoMedics looks to increase distribution worldwide via its extensive network in over 60 countries. We look forward to an exciting year ahead for the Company as our products enter the vast consumer wellness market, which in turn contributes to potentially increasing value for the SPO shareholders."

About SPO

SPO is a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-enhancing information within four key markets: medical care; sports and wellness; homecare monitoring and security. Its patented technology uses information gathered from the reflectance of light on the human body, in a noninvasive manner, to monitor key vital signs. The company manufactures its products in addition to licensing its technologies to appropriate client corporations for commercialization and distribution. For more information, visit http://www.spoglobal.com.

Forward Looking Statements

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, expectations as to  the realization of additional revenues from the order backlog, expectations as to increasing the order backlog in 2013, the success of efforts to expand distribution of our products, the success, if any, of our efforts to expand distribution of products to additional mass market retailers, the ability to create strategic partnerships to aid in the distribution of products, profitability, market acceptance of our products and new product applications, timing of new product launches, success of the Company's re-branding program, product performance, size of prospective markets, revenue assessments, marketing strategies, success of our restructured operations and plans, our ability to generate fees or raise capital to support our business operations and plan, the sufficiency and availability of working capital, changes in economic conditions generally and in more specifically, the introduction of competing products, changes in our operating strategy or development plans patent protection for our products and technologies, changes in economic conditions generally and in more specifically, in the markets we operate, changes in technology, legislative or regulatory changes that affect us and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2012. We undertake no obligation to revise or update any forward-looking statement for any reason."

This was an exciting release for investors because it shows that the company is moving along the right track to continue its growth process. Penny Stock Dream will continue to watch what comes here closely, as time progresses and highly suggest that others interested in buying penny stocks do the same. If greater attention comes here and the stock does indeed see greater volume pouring in, this may become an incredible story to tell.

Our platform aims to bring only the best penny stock information to our subscribers, so that they can all make more informed decisions when it comes to their research regarding penny stock investment. SPOM (Spo Medical, Inc.) has provided incredible gains lately and although we have not previously released an alert for it, we do periodically write pieces on fast moving penny stocks, to the readers of our blog and to the subscribers of our newsletter. General subscription to our newsletter service is absolutely free, so we highly suggest that those investors most interested in buying penny stocks, as well as anyone who is simply interested in learning how to trade penny stocks, take the time to subscribe to this free service. You can subscribe to our top penny stock newsletter platform at www.pennystockdream.com.

While our general penny stock newsletter subscription services are absolutely free, many highly successful traders have opted to sign up to our elevated Platinum Membership services, for the purpose of receiving various special alerts in advance of free members. This has given them a significant advantage in their ability to digest key information before many others are able to. Those wishing to sign up to our special Platinum Membership package, can do so at www.pennystockdream.com/platinum.

 

Pennystockdream.com and its employees are not registered as Investment Advisers in any jurisdiction whatsoever. We encourage all of those that are interested in trading penny stocks, or any other form of investment, to conduct their own research to garner a better understanding of what they are getting involved in. Be sure to read the full pennystockdream.com disclaimer at: http://pennystockdream.com/disclaimer.